Optimizing Long-term Survival in Organ Transplantation: From Physiopathology to Optimized Patient Management
BIOSUPORT
1 other identifier
interventional
430
1 country
4
Brief Summary
Increased indications for transplantation continue to worsen the shortage of organs and need the extension of graft sampling criteria and the search for new potential sources of organs. Despite undeniable success in the short term, due to major advances in surgery, medicine and research, transplant recipients continue to face the risk of chronic rejection and long-term complications. The University Hospital Federation "FHU SUPORT" was created to optimize the chances of success of the organ transplant and improve the quality of life of the transplanted patient. FHU SUPORT 's ambition is based on a translational strategy that presents two priority areas: Axis 1: Optimization, evaluation, conditioning of the donor, graft, recipient Axis 2: Personalized follow-up of the transplanted patient in the short and long term Identifying factors for long-term graft and patient survival through translational research from a common cohort and biological collection will predict transplant rejection, prolong graft function, or improve the patient's care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Dec 2020
Longer than P75 for not_applicable
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 24, 2019
CompletedFirst Posted
Study publicly available on registry
June 25, 2019
CompletedStudy Start
First participant enrolled
December 21, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2025
CompletedMarch 29, 2024
March 1, 2024
4.1 years
June 24, 2019
March 28, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Survival of the graft
12 months
Study Arms (1)
blood, bile and urine samples
EXPERIMENTALblood and urine samples at D0,D1, D3 D7, D14, M1, M3, M6 and M12
Interventions
various blood and urine samples will be collected from the recipient at D0, D7, D14, M1, M3, M6 and M12 and intraoperative bile collection
Eligibility Criteria
You may qualify if:
- Male or female over 18 (no age limit)
- affiliated to a social security organization
- Recipient (s) of a kidney, liver or heart transplant
- followed by at least one of the FHU SUPORT centers (Tours, Poitiers, Limoges, Rennes)
- having given informed consent to participate in the cohort.
You may not qualify if:
- Patient unable to understand the information given by the investigator
- People under the protection of justice
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Limoges hospital
Limoges, France
Poitiers Hospital
Poitiers, 86000, France
Rennes Hospital
Rennes, 35000, France
Tours hospital
Tours, 37000, France
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 24, 2019
First Posted
June 25, 2019
Study Start
December 21, 2020
Primary Completion
February 1, 2025
Study Completion
November 1, 2025
Last Updated
March 29, 2024
Record last verified: 2024-03
Data Sharing
- IPD Sharing
- Will not share